Kusurinomadoguchi (5592) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Nov, 2025Executive summary
Achieved increased revenue and profit for the first half of FY2026, driven by strong recurring (stock) sales across core business segments.
Net income attributable to parent company shareholders surged due to additional deferred tax assets from capital reduction.
Cost optimization and subsidiary rationalization led to record-high operating profit, with SG&A expenses and headcount decreasing year-over-year and sequentially.
Financial highlights
Consolidated revenue for the first half: ¥5,825 million, up 7% year-over-year; Q2 revenue: ¥2,910 million, up 3% YoY.
Operating income for the first half: ¥1,262 million, up 33% YoY; Q2: ¥632 million, up 11% YoY.
Net income attributable to parent company shareholders: ¥1,620 million for the first half, up 288% YoY; Q2: ¥1,233 million, up 288% YoY.
EBITDA: ¥959 million, up 12% YoY.
Gross margin improved in key segments, with media business gross margin rising from 34% to 43% and "Minna no Okusuri Bako" business from 47% to 51%.
Outlook and guidance
FY2026 full-year revenue forecast: ¥12,300 million (+10% YoY); operating income forecast: ¥2,200 million (+12% YoY); net income forecast: ¥2,240 million (+10% YoY).
Progress rates at Q2: revenue 47%, operating income 57%, net income 72% of full-year targets.
Annual dividend planned at ¥30 per share.
Mid-term plan targets ¥20 billion in recurring sales and ¥5 billion in operating profit by FY2030.
Latest events from Kusurinomadoguchi
- Record profit and revenue growth drive higher guidance and dividend, fueled by digital healthcare and acquisitions.5592
Q3 202613 Feb 2026 - Q1 FY2025 revenue up 22.1% YoY, but profit fell due to higher SG&A from acquisitions.5592
Q1 20258 Sep 2025 - Revenue up 28% YoY, profit growth, digital healthcare demand, and guidance maintained.5592
Q2 20258 Sep 2025 - Strong profit and revenue growth, improved financials, and robust digital healthcare outlook.5592
Q4 20258 Sep 2025 - Record Q1 revenue and profit growth with strong margins; full-year guidance unchanged.5592
Q1 20268 Sep 2025 - Record Q3 profit and revenue drive upward revision of full-year outlook and dividend.5592
Q3 20258 Sep 2025